14 February 2023
Event Date(s)/Period(s)
14 February 2023
Organised by
AIDS Institute (co-organiser)
HIV/AIDS remains an incurable human infectious disease. With support of Theme-based Research Scheme, scientists at HKU AIDS Institute invented the PD1-enhanced AIDS vaccine, namely ICVAX, as a novel immunotherapy of potentiating host immunity to achieve a functional cure, a state of suppressed viremia below detection limit for a prolonged period in HIV-infected patients without receiving antiretroviral treatment. With approvals by China FDA and institutional ethical committee, the collaborative research team officially announced the launching of a Phase I clinical trial of GMP-grade ICVAX at the symposium, highlighting the first anti-HIV biomedical product invented by an HKU research team to benefit patients from the stages of clinical trials. The event was co-organised by Immuno Cure HK Ltd, 3rd People’s Hospital of Shenzhen and HKU AIDS Institute.
Follow HKUMed